Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom
© 2022. The Author(s)..
Population-based studies can provide important evidence on the safety of COVID-19 vaccines. Using data from the United Kingdom, here we compare observed rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2 and infection with SARS-CoV-2 with background (expected) rates in the general population. First and second dose cohorts for ChAdOx1 or BNT162b2 between 8 December 2020 and 2 May 2021 in the United Kingdom were identified. A further cohort consisted of people with no prior COVID-19 vaccination who were infected with SARS-Cov-2 identified by a first positive PCR test between 1 September 2020 and 2 May 2021. The fourth general population cohort for background rates included those people in the database as of 1 January 2017. In total, we included 3,768,517 ChAdOx1 and 1,832,841 BNT162b2 vaccinees, 401,691 people infected with SARS-CoV-2, and 9,414,403 people from the general population. An increased risk of venous thromboembolism was seen after first dose of ChAdOx1 (standardized incidence ratio: 1.12 [95% CI: 1.05 to 1.20]), BNT162b2 (1.12 [1.03 to 1.21]), and positive PCR test (7.27 [6.86 to 7.72]). Rates of cerebral venous sinus thrombosis were higher than otherwise expected after first dose of ChAdOx1 (4.14 [2.54 to 6.76]) and a SARS-CoV-2 PCR positive test (3.74 [1.56 to 8.98]). Rates of arterial thromboembolism after vaccination were no higher than expected but were increased after a SARS-CoV-2 PCR positive test (1.39 [1.21 to 1.61]). Rates of venous thromboembolism with thrombocytopenia were higher than expected after a SARS-CoV-2 PCR positive test (5.76 [3.19 to 10.40]).
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Nature communications - 13(2022), 1 vom: 23. Nov., Seite 7167 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Burn, Edward [VerfasserIn] |
---|
Links: |
---|
Themen: |
BNT162 Vaccine |
---|
Anmerkungen: |
Date Completed 28.11.2022 Date Revised 28.12.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41467-022-34668-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM349313881 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM349313881 | ||
003 | DE-627 | ||
005 | 20231226042325.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41467-022-34668-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1164.xml |
035 | |a (DE-627)NLM349313881 | ||
035 | |a (NLM)36418291 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Burn, Edward |e verfasserin |4 aut | |
245 | 1 | 0 | |a Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 28.11.2022 | ||
500 | |a Date Revised 28.12.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022. The Author(s). | ||
520 | |a Population-based studies can provide important evidence on the safety of COVID-19 vaccines. Using data from the United Kingdom, here we compare observed rates of thrombosis and thrombocytopenia following vaccination against SARS-CoV-2 and infection with SARS-CoV-2 with background (expected) rates in the general population. First and second dose cohorts for ChAdOx1 or BNT162b2 between 8 December 2020 and 2 May 2021 in the United Kingdom were identified. A further cohort consisted of people with no prior COVID-19 vaccination who were infected with SARS-Cov-2 identified by a first positive PCR test between 1 September 2020 and 2 May 2021. The fourth general population cohort for background rates included those people in the database as of 1 January 2017. In total, we included 3,768,517 ChAdOx1 and 1,832,841 BNT162b2 vaccinees, 401,691 people infected with SARS-CoV-2, and 9,414,403 people from the general population. An increased risk of venous thromboembolism was seen after first dose of ChAdOx1 (standardized incidence ratio: 1.12 [95% CI: 1.05 to 1.20]), BNT162b2 (1.12 [1.03 to 1.21]), and positive PCR test (7.27 [6.86 to 7.72]). Rates of cerebral venous sinus thrombosis were higher than otherwise expected after first dose of ChAdOx1 (4.14 [2.54 to 6.76]) and a SARS-CoV-2 PCR positive test (3.74 [1.56 to 8.98]). Rates of arterial thromboembolism after vaccination were no higher than expected but were increased after a SARS-CoV-2 PCR positive test (1.39 [1.21 to 1.61]). Rates of venous thromboembolism with thrombocytopenia were higher than expected after a SARS-CoV-2 PCR positive test (5.76 [3.19 to 10.40]) | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a BNT162 Vaccine |2 NLM | |
650 | 7 | |a COVID-19 Vaccines |2 NLM | |
700 | 1 | |a Li, Xintong |e verfasserin |4 aut | |
700 | 1 | |a Delmestri, Antonella |e verfasserin |4 aut | |
700 | 1 | |a Jones, Nathan |e verfasserin |4 aut | |
700 | 1 | |a Duarte-Salles, Talita |e verfasserin |4 aut | |
700 | 1 | |a Reyes, Carlen |e verfasserin |4 aut | |
700 | 1 | |a Martinez-Hernandez, Eugenia |e verfasserin |4 aut | |
700 | 1 | |a Marti, Edelmira |e verfasserin |4 aut | |
700 | 1 | |a Verhamme, Katia M C |e verfasserin |4 aut | |
700 | 1 | |a Rijnbeek, Peter R |e verfasserin |4 aut | |
700 | 1 | |a Strauss, Victoria Y |e verfasserin |4 aut | |
700 | 1 | |a Prieto-Alhambra, Daniel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 13(2022), 1 vom: 23. Nov., Seite 7167 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:23 |g month:11 |g pages:7167 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-022-34668-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2022 |e 1 |b 23 |c 11 |h 7167 |